
Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic breast cancer.

Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic breast cancer.

Updated 96-week data from the ASC4FIRST trial show asciminib significantly outperforms standard TKIs in major molecular response for patients with CML.

Fixed-duration, subcutaneous epcoritamab-bysp achieved durable responses with a manageable safety profile in older patients with newly diagnosed large B-cell lymphoma who are not candidates for anthracycline-based therapy.

A study of 9,146 patients found no OS difference among first-line CDK4/6 inhibitor combinations for HR+/HER2- metastatic breast cancer, presented at SABCS 2024.

Data presented at ASH 2024 showed that tafasitamab led to a progression-free survival of 11.3 months and an overall survival of 24.8 months in patients with relapsed/refractory DLBCL.

Treatment with anitocabtagene autoleucel produced durable efficacy in patients with relapsed/refractory multiple myeloma.

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, overall cardiac adverse events, and heart failure in patients with B-cell hematologic malignancies.

Iopofosine I-131 delivered lasting efficacy and was well-tolerated in heavily pretreated patients with relapsed/refractory Waldenström macroglobulinemia.

Real-world data suggest optimal CLL/SLL treatment sequencing involves targeted therapies, including covalent BTKis and BCL2 inhibitors, for better survival outcomes.

Brexucabtagene autoleucel showed comparable efficacy outcomes in patients aged 60 to 69 with relapsed/refractory B-cell acute lymphoblastic leukemia and those under 60.

Cladribine plus venetoclax improved complete response and CR with incomplete count recovery rates in MRD-negative patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.

Pirtobrutinib, venetoclax, and obinutuzumab demonstrated a numerically higher rate of undetectable minimal residual disease vs ibrutinib and venetoclax in chronic lymphocytic leukemia.

Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen receptor-positive/HER2-negative metastatic breast cancer treatment.

Findings from a phase 1b study showed that the combination of IO-202 and azacitidine elicited clinical benefits in patients with hypomethylating agent–naive chronic myelomonocytic leukemia.

In the phase 2 SOLTI VALENTINE trial, patritumab deruxtecan with or without letrozole showed similar efficacy to multiagent chemotherapy in HR-positive, HER2-negative breast cancer with fewer severe adverse events.

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, following various risk management measures.

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as reported in findings from a single-arm phase 2 trial.

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, according to 6-year data from the OlympiA trial.

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual Meeting.

SHR-A1811 showed promising antitumor activity and acceptable tolerability in patients with HER2-positive breast cancer, according to results of the phase 2 FASCINATE-N trial.

T-DXd improves progression-free survival vs physician’s choice, regardless of time to progression or endocrine resistance, in HR-positive, HER2-low/-ultralow metastatic breast cancer.

Arlocabtagene autoleucel led to antitumor activity and an acceptable safety profile in heavily pretreated relapsed/refractory multiple myeloma, according to updated phase 1 trial data.

At the 2024 ASH Annual Meeting, findings suggested that the IPSS-del(5q) Scoring System may more effectively identify risks in MDS with isolated 5q deletions compared to standard MDS scoring systems.

The phase 2 ZUMA-2 trial demonstrated that brexucabtagene autoleucel led to a high objective response rate in patients with relapsed/refractory mantle cell lymphoma.

Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.

Immediate surgery significantly lowered local recurrence rates in elderly patients with breast cancer compared with delayed surgery, according to a meta-analysis presented at SABCS 2024.

Socioeconomic factors significantly impact access to allogeneic hematopoietic stem cell transplant in patients with acute myeloid leukemia, with certain groups less likely to receive this potentially lifesaving treatment.

Updated phase 2 trial data presented at the 2024 ASH Annual Meeting show that the novel bicistronic CD19/CD22-directed CAR T-cell therapy is safe, durable, and highly effective in children with relapsed/refractory B-ALL.

Selinexor with ruxolitinib demonstrated encouraging efficacy with a manageable safety profile in patients with myelofibrosis who were previously treated with ruxolitinib.

The induction regimen of isatuximab plus RVd significantly improved progression-free survival vs RVd alone in transplant-eligible patients with newly diagnosed multiple myeloma.